Xencor pockets $45 million in new funding round

Xencor has completed a $45 million round of investment. MedImmune Ventures, Novo Nordisk, and HealthCare Ventures all participated with existing investor Zen Investments. This brings total venture funds raised by Xencor to $130 million. Most of the most will go to its drug development programs. Xencor was a 2005 Fierce 15 winner.

- here's the report from SoCalTech

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.